Reviewing Tilray (TLRY) & Its Competitors

Tilray (NASDAQ: TLRY) is one of 33 public companies in the “Medicinals & botanicals” industry, but how does it contrast to its competitors? We will compare Tilray to related companies based on the strength of its risk, institutional ownership, analyst recommendations, dividends, profitability, earnings and valuation.

Earnings and Valuation

This table compares Tilray and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Tilray $166.98 million -$321.17 million -3.29
Tilray Competitors $218.50 million -$99.79 million 1.73

Tilray’s competitors have higher revenue and earnings than Tilray. Tilray is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Tilray and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tilray -259.60% -77.77% -21.45%
Tilray Competitors -163.69% -267.59% -46.37%

Volatility & Risk

Tilray has a beta of 2.92, suggesting that its stock price is 192% more volatile than the S&P 500. Comparatively, Tilray’s competitors have a beta of 2.56, suggesting that their average stock price is 156% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Tilray and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tilray 1 12 2 0 2.07
Tilray Competitors 136 361 413 14 2.33

Tilray currently has a consensus target price of $12.73, indicating a potential upside of 128.91%. As a group, “Medicinals & botanicals” companies have a potential upside of 95.11%. Given Tilray’s higher probable upside, analysts clearly believe Tilray is more favorable than its competitors.

Insider and Institutional Ownership

10.4% of Tilray shares are held by institutional investors. Comparatively, 21.6% of shares of all “Medicinals & botanicals” companies are held by institutional investors. 16.8% of Tilray shares are held by insiders. Comparatively, 25.8% of shares of all “Medicinals & botanicals” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Tilray competitors beat Tilray on 9 of the 13 factors compared.

Tilray Company Profile

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Nanaimo, Canada.

Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.